Pharma BD Deal Intelligence
A $150M oncology bet that turned into a near-total write-off within one quarter, and both lead assets were dead within a few years as Biogen abandoned oncology altogether
Full analysis, sources & comparables →The deal — $150M closing plus $100M in milestones — gives Biogen Idec an oncology platform around HSP90 antagonists and integrates Conforma's 40 employees into…
Conforma's VP of corporate development said the $250M buyout grew out of strategic partnership discussions rather than financing necessity — Conforma was…
Despite roughly two decades of clinical development across multiple sponsors, no HSP90 inhibitor has achieved FDA approval, with hepatic and ocular toxicities…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Oncology HSP90 inhibitors; $150M upfront + up to $100M milestones
A $150M oncology bet that turned into a near-total write-off within one quarter, and both lead assets were dead within a few years as Biogen abandoned oncology altogether
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Idec Inc. / Conforma Therapeutics Corporation (this deal) | 2006 | $250M | 11 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals